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INTRODUCTION
Angiogenesis, the formation and growth of new capillary blood vessels, is normally under stringent control. Expansion of the capillary bed by angiogenesis is in the healthy adult limited to wound healing, physiological growth of tissues (e.g. fat, skeletal muscle) and cyclic variations in the endometrium and the corpus luteum (Hori et al. 1996 , Andrade et al. 1997 , Kilarski et al. 2012 . By contrast, uncontrolled angiogenesis can often been seen as a contributing factor in a number of angiogenesis-dependent pathologies, such as tumor growth, proliferative retinopathies, rheumatoid arthritis and psoriasis (Kilarski et al. 2012) .
Stimuli such as carbon dioxide, nitric oxide, hypoxia or the increased metabolic demands associated with exercise work through multiple pathways regulate angiogenesis in a complex Thalidomide (α-N-phthalimido glutarimide) is a glutamic acid derivative that was first introduced in 1954 as a sedative drug but was withdrawn from the market due to its teratogenic effects. Thalidomide has various pharmacological properties such as immunomodulatory, antiinflammatory and antiangiogenic activity and it has been used successfully for various inflammatory and autoimmune diseases and some tumors (Amirshahrokhi and Ghazi-Khansari 2012).
A variety of animal models have been described to provide more quantitative analysis of in vivo angiogenesis and to characterize pro-and antiangiogenic molecules (Andrade et al. 1997) . The assays for angiogenesis that are frequently used include the chick chorioallantoic membrane (CAM), transparent chambers, matrix or sponge implants and the cornea model. All utilize the pre-existing vasculature as a source of vessels that expand into an implanted or injury-induced matrix. However, none of these methods and their modifications are ideal as they are difficult to quantify or observe vascular growth continuously. It is necessary to establish a quantitative, reproducible and specific method for studies of angiogenesis factors and inhibitors (Andrade et al. 1987 ).
The present study aimed to evaluate and quantify the angiogenic potential of thalidomide, by in vivo mice sponge implantation assay. This method was chosen to be standardized as it was reproducible, not dependent on the observer's experience, and could be applied in the Faculdade de Medicina do ABC (Andrade et al. 1997 , Ferreira et al. 2004 , Schönherr et al. 2004 ). OBJECTIVES 1) To standardize a method for the study of angiogenesis.
2) To investigate the effects of thalidomide on angiogenesis.
MATERIALS AND METHODS
Animals from the Faculdade de Medicina do ABC were used. Throughout the experiment, all animals were maintained on a 12:12-h light-dark cycle, under controlled temperature and humidity conditions and with free access to food and water. The experimental protocol was approved by the Ethical Committee for Animal Experimentation (EAEC). Efforts were made to minimize animal suffering and to reduce the number of animals used. Animals were monitored daily.
EVALUATION OF ANGIOGENESIS
After seven days, the mice were anesthetized as previously described. A blood sample from circulation was obtained in order to compare both hemoglobin values from serum and sponge. The sponges were carefully removed and the contents were homogenized in 2.0 mL of saline and centrifuged at 10,000 x g for 15 minutes. The supernatant was filtered through a 0.22 micron filter (Millipore). Hemoglobin concentration was determined spectrophotometrically at 540 nm by using the hemoglobin assay kit (Sigma Drabkin´s reagent).
STATISTICAL ANALySIS
Hemoglobin content in sponge and in serum was tested using nonparametric Mann-Whitney test. GBstat 9.0 software was used. p < 0.05 was considered statistically significant. Table I shows ratio between hemoglobin values obtained in sponge and in serum. It is possible to verify that the sponge-induced angiogenesis can be suppressed by thalidomide. However, in spite of promising results obtained from animal models, many therapies have failed when applied in the clinic. These discrepancies suggest that current in vivo angiogenesis assays should be improved in order to better understand mechanisms nondevelopmental angiogenesesis during tissue vascularization and repair (Kilarski et al. 2012) . Moreover, one of the difficulties of current methods of measuring angiogenesis is the assessment of vascularization which is usually to subjective to be reproducible between laboratories and even between individuals (Andrade et al. 1987) .
RESULTS
This paper describes a quantitative method for the study of angiogenesis in mice. It was adapted from Andrade et al. (1987 Andrade et al. ( , 1997 and it offers several advantages: (i) an objective assessment of angiogenesis; (ii) reproducibility and (iii) evaluation of angiogenesis by comparison between hemoglobin content in serum and in sponge.
We have shown that the sponge-induced angiogenesis can be suppressed by thalidomide. Thalidomide is listed as a drug that potentially would target multiple components of tumor microenvironment (angiogenesis, inflammation, DAVID FEDER et al. proliferative activity). Despite these wellcharacterized effects and a large number of publications, the results of the effects of thalidomide on a number of clinical and experimental protocols are rather contradictory and/or inconsistent (Souza et al. 2012) .
Thalidomide was approved by the FDA for the treatment of erythema nodosum leprosum (ENL) and multiple myeloma. It has also been demonstrated that thalidomide or its analogs are effective in the treatment of rheumatoid arthritis, Crohn's disease, prostate cancer, Behcet's disease, chronic host-versus-graft disease, lupus erythematosis and HIV-associated oral ulcers. However, teratogenicity, peripheral neuropathy and other adverse effects of thalidomide have led to the design of its new analogs with low toxicity (Amirshahrokhi and Ghazi-Khansari 2012).
The mechanism of thalidomide action is not yet known, but hypotheses include decreased levels of tumor necrosis factor (TNF), interleukin and inhibition of production and co-stimulation of CD8. Reports also suggest that thalidomide has a role in regulating helper cells (Th2). This would increase the production of Th2 cytokines IL4 and IL5 and inhibit the production of inflammatory lymphocytes (Th1) cytokine IFN and range in peripheral blood cells stimulated by antigens and mitogens (Pridgeon and Drake 2005) . Laboratory studies performed with rabbit cornea show that thalidomide has antiangiogenic properties, possibly by blocking the action of potent angiogenic factors such as fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). In vitro studies have suggested that the inhibitory effect of angiogenesis is caused by certain metabolites formed in vivo rather than the parent compound. Another possibility suggests that inhibition of TNF-α may also be responsible for inhibiting angiogenesis, since TNF-α has a positive effect on angiogenesis (Kumar and Chhibber 2011). 2) Sponge-induced angiogenesis can be suppressed by thalidomide.
RESUMO
No adulto, a angiogênese é restrita a poucas condições Avaliou-se a quantidade de hemoglobina na esponja e na circulação. A razão obtida entre esses valores foi testada por meio do teste não paramétrico Mann-Whitney.
Os resultados mostraram que a angiogênese induzida pela esponja e quantificada por meio da razão hemoglobina esponja/circulação é um modelo útil para estudos in vivo de angiogênese. Além disso, observou-se que a angiogênese induzida pela esponja diminui na presença de talidomida, corroborando para a validação do método padronizado.
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